FDA approves first medication to help reduce allergic reactions to multiple foods

Omalizumab (Xolair) injection is indicated for patients ages one year and older with an IgE-mediated food allergy to reduce risk of Type 1 allergic reactions, including anaphylaxis risk that may occur following accidental exposure to one or more foods. Patients taking Xolair for food allergies must continue to avoid all foods that may cause allergies. The drug is intended for repeated use to reduce the risk of allergic reactions, but shouldn't be taken as an emergency treatment for allergic reactions, including anaphylaxis.